Stocks Health care SDGR
NASDAQ · Health careSchrodinger, Inc. (SDGR)
Schrodinger, Inc. brought in $259M of revenue over the twelve months to June 30, 2026, up 8.9% from a year earlier. It posted a net loss of $54.3M. Operating cash flow minus capital spending left $12.5M of free cash flow in fiscal 2025. At June 30, 2026 it held $287.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Schrodinger, Inc. does
Schrodinger, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SDGR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $255.9M | -$103.3M | -$1.41 | $12.5M |
| 2024 | $207.5M | -$187.1M | -$2.57 | -$164.7M |
| 2023 | $216.7M | $40.7M | $0.54 | -$150.1M |
| 2022 | $181M | -$149.2M | -$2.10 | -$127.7M |
| 2021 | $137.9M | -$100.4M | -$1.42 | -$77.8M |
| 2020 | $108.1M | -$24.5M | -$0.41 | $14.2M |
Where SDGR ranks in Health care
Latest SEC filings
What Schrodinger, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- June 29, 2026
- June 23, 2026
- June 8, 2026
- May 20, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026
- May 5, 2026
What is SDGR worth? A DCF from its reported cash flow
Insider trades
What the people running Schrodinger, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $928K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 17, 2026 | Akinsanya KarenSee Remarks | Exercised options | 31,599 | $137.1K |
| September 17, 2026 | Akinsanya KarenSee Remarks | Soldpre-planned (10b5-1) | 10,000 | $280K |
| September 17, 2026 | Akinsanya KarenSee Remarks | Soldpre-planned (10b5-1) | 21,599 | $648K |
Questions about SDGR
What does Schrodinger, Inc. do?
Schrodinger, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SDGR.
Is Schrodinger, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $54.3M on revenue of $259M.
How much revenue does Schrodinger, Inc. make?
Over the twelve months to June 30, 2026 Schrodinger, Inc. reported revenue of $259M. That is 8.9% more than a year earlier.
When did Schrodinger, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 21, 2026.
Similar companies
Compare SDGR with
Follow SDGR
Get an email when Schrodinger, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow SDGR: get an email when it filesWhere the numbers come from
Financial figures are the values Schrodinger, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.